Kalaris Therapeutics Files 8-K on Financials
Ticker: KLRS · Form: 8-K · Filed: May 14, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: KLRS
TL;DR
Kalaris Therapeutics (KLRS) filed an 8-K on May 14th, updating on financials. Check it out.
AI Summary
Kalaris Therapeutics, Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Allovir, Inc. and ViraCyte, Inc., is incorporated in Delaware and headquartered in Palo Alto, California.
Why It Matters
This filing provides investors with an update on Kalaris Therapeutics' financial performance and condition, which is crucial for assessing the company's ongoing operations and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or high-risk events.
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Registrant
- May 14, 2025 (date) — Date of Report
- Allovir, Inc. (company) — Former Company Name
- ViraCyte, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Palo Alto, California (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing date for this 8-K is May 14, 2025.
What is Kalaris Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 628 Middlefield Road, Palo Alto, California 94301.
Has Kalaris Therapeutics, Inc. operated under different names previously?
Yes, it was formerly known as Allovir, Inc. (name change effective 20190521) and ViraCyte, Inc. (name change effective 20180924).
What is the SIC code for Kalaris Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding Kalaris Therapeutics, Inc. (KLRS).